Tyra Biosciences to Host Conference Call on SURF302 Study Findings
News provided byTyra Biosciences, Inc · 1 min read
CARLSBAD, Calif., Sept. 4, 2026 /CourierPR/ -- Tyra Biosciences, a clinical-stage biotechnology company, is set to host a conference call and webcast on September 9, 2026, to discuss initial findings from the SURF302 Phase 2 study of oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC). The event, scheduled for 8:00 am Eastern Time, will provide insights into the early results of this important clinical trial.
Participants can access the live webcast and associated slide presentation on the "For Investors" page of Tyra Biosciences’ website at https://ir.tyra.bio. Those interested in joining the conference call via telephone must register in advance at the provided link. Upon registration, attendees will receive a confirmation email with the necessary details, including a dial-in number, a unique passcode, and a registrant ID for access.
Dabogratinib, the compound under scrutiny, is a potential first-in-class selective FGFR3 inhibitor developed by Tyra Biosciences. The company's internal precision medicine platform, SNÅP, enables rapid and precise drug design, contributing to the development of this and other clinical-stage programs targeting FGFR biology. Notably, the SNÅP platform is key to designing and predicting which candidates may demonstrate the highest potency, selectivity, and tolerability.
Tyra Biosciences is advancing multiple clinical-stage programs, including oral dabogratinib for LG-UTUC, IR NMIBC, and ACH, as well as TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, and TYRA-200, an oral, investigational FGFR1/2/3 inhibitor. These programs are being evaluated in the SURF431 and SURF201 studies, respectively, for advanced hepatocellular carcinoma and metastatic intrahepatic cholangiocarcinoma.
The conference call and webcast will offer a critical update on the progress of these initiatives and the potential of oral dabogratinib for IR NMIBC. The results are expected to provide valuable information to investors and stakeholders, highlighting the company's commitment to precision medicine in the treatment of complex cancers.